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Abstract. Background and aim: Children with heterozygous familial hypercholesterolemia (heFH) are at risk 
of premature atherosclerosis. Aims of this study were: (a) to longitudinally evaluate the endothelial dysfunc-
tion, estimated through brachial flow mediated dilation (FMD), as first sign of subclinical atherogenesis in 
a group of children and adolescents affected by heFH in comparison to normo-lipidemic controls, and (b) 
to identify predictive factors influencing the endothelial function and its development in the same cohort of 
patients. Methods: This is a prospective, longitudinal and cross-sectional study. Physical examination, plasma 
lipid profile and brachial artery FMD were measured at baseline and after follow-up. Results: At baseline, 
FMD did not differ between heFH children (n.24, median age 9.71) and controls (n. 24, median age 10.29) 
(7.67 ± 9.26 vs. 11.18 ± 7.28 %, p 0.09). Nevertheless, during follow-up (median length of lipid-lowering diet 
4.52 years), FMD got worse in 54% of heFH subjects and its worsening correlated to the increasing of low-
density lipoprotein cholesterol (r -0.21, p < 0.05). Moreover, being male (β -0.46, p 0.03), undergoing puberty 
(β -0.61, p 0.03) and increasing of body mass index standard deviation score (β -0.39, p 0.03) were identified 
as main independent predictor factors of FMD drop. Conclusions: During the first decades of life, not only 
hypercholesterolemia, but also clusters of pro-atherogenic conditions and their persistence, could affect the 
endothelial function and its trend. (www.actabiomedica.it)
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Introduction
Familial hypercholesterolemia (FH) (OMIM 
143690) is an inborn, autosomal and monogenic disor-
der of lipoprotein pathway. Affected patients presented 
high levels of total cholesterol (TC) and abnormal 
increased concentration of low-density lipoprotein 
(LDL) cholesterol (LDL-C). Clinically, even if rare in 
childhood and adolescence, symptoms of cholesterol 
deposits in tissues can be detected (planar and tuber-
ous xanthomas on the extensor tendons of the hands 
and feet and xanthelasma palpebrarum) together with 
premature cardiovascular diseases (pCVD)1. The prev-
alence of heterozygous FH (heFH) in general popula-
tion ranges from 1 in 300 to 1 in 500, although this 
figure rises within certain ethnic groups2. The most 
frequent cause of FH is attributable to mutations of 
the LDL receptor gene (LDL-R). More than 1700 
mutations of this gene have been reported to date3, 
ranging from single-nucleotide substitutions to large 
deletions, leading to a variety of gain-of-function or 
loss-of-function LDL-R4,5. In addition to LDL-R 
defects, a similar phenotype can be caused by a number 
of mutations in the apolipoprotein B100 (ApoB100) 
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gene (that disrupt the binding of the LDL particle to 
the LDL-R) and by gain of function mutations in the 
proprotein convertase subtilisin/kexin type 9 (PCSK9) 
gene (that increase LDL-R degradation) 6, 7.
It is already documented that elevated levels of 
LDL-C are one of the major risk factor of CVD 8. 
Despite availability of an effective pharmaceutical 
approach, among FH patients, current age- and sex-
standardized mortality due to CVD is about 5 times 
greater than general population9. Although the abso-
lute risk of CVD during childhood is low 1, data com-
ing from autopsy of healthy adolescents have revealed 
that early markers of atherosclerosis already exist at 
that age10. Nevertheless, only few data documenting 
early morphological (like fatty streak formation) and 
subclinical functional vascular abnormalities in FH 
children can be found11,12. Endothelial dysfunction, 
evaluated through flow-mediated dilation (FMD), 
seems to represent the earliest sign of atherogenesis 
and is documentable in patients at risk, even in absence 
of classical and clinical CVD signs 13. 
Taking into account all these considerations, the 
objectives of our study are: (a) longitudinal evaluation 
of the endothelial dysfunction, estimated through bra-
chial FMD, as first sign of subclinical atherogenesis in 
a group of heFH children and adolescents in compari-
son to healthy controls and (b) identification of addi-
tional predictive factors of endothelial dysfunction, its 
progressive development and, consequently, the risk of 




This prospective, longitudinal, and cross-sectional 
study includes 24 Caucasian children and adolescents 
(median age 9.71, range 4.2 – 19.53 years, 12 boys) with 
genetically identified heFH and 24 normolipidemic 
healthy Caucasian controls, matched by sex and age 
(median age 10.29, range 2 – 16 years, 12 boys) attending 
the Paediatric Lipid Clinic of the University of Modena 
and Reggio Emilia, Italy. The clinical diagnosis of heFH 
was based on internationally recognized criteria14 and 
then genetically confirmed. Exclusion criteria for both 
heFH patients and controls include: presence of acute 
infection, diabetes, hypertension or other metabolic 
and/or endocrine disease, use of any medications and 
smoking. After diagnosis, all heFH patients followed 
a lipid-lowering diet according to the American Heart 
Association (AHA) updated dietetic guidelines15. In the 
proposed Therapeutic Lifestyle Changes (TLC) diet, 
approximately 30% of calories have to derive from fat 
(less than 7% from saturated fat) and the total intake of 
cholesterol has to be limited to 200 mg/day7. None of the 
patients was on statin or other lipid-lowering therapy. 
The study was conducted in accordance with the 
Declaration of Helsinki. Each subject and/or their 
parents gave informed consent to the study, which was 
approved by the local committee (Area Vasta Emilia 
Nord, Italy) on ethical practice protocol code 262/11. 
Study design
A detailed medical history and a familial history 
of precocious CVD were obtained from all participants 
using a standardized report form. CVD happened 
before 55 years in males and 65 years in females were 
considered as premature CVD (pCVD) and, thus, the 
family history was defined as positive for pCVD.
Physical examination included an accurate auxo-
logical evaluation. Height was measured to the nearest 
0.1 cm with a wall-mounted stadiometer (Harpenden, 
Crymych, UK). Body weight was measured to the near-
est 0.1 kg and body mass index (BMI) was obtained 
from the weight in kg/height in meters squared and 
expressed, as well as height, as mean ± SDS with 
respect to chronological age and using national growth 
charts16. Pubertal development was determined using 
the grading system defined by Tanner17.
Plasma lipid profile was performed in all patients 
at baseline. Blood samples were collected early in the 
morning after overnight fasting. Moreover, at baseline, 
all the enrolled patients and all the controls underwent 
an evaluation of endothelial function through brachial 
FMD. After follow-up (median duration 4.52 years), 
during which all heFH patients followed a lipid-lower-
ing diet according to TLCs, physical examination and 
plasma lipid profile, brachial FMD were re-assessed in 
heFH patients. 
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Laboratory Methods
Plasma concentrations of TC, LDL-C, triglyc-
erides (TG) and high-density lipoprotein choles-
terol (HDL-C) were measured enzymatically using 
commercial kits (Cholesterol CHOD-PAD, HDL 
plus, Triglycerides GPO-PAP; Hitachi, Roche 
Diagnostic). The sensitivity of the TC, HDL-C, 
and LDL-C assay was 3 mg/ml. Intra- and inter-
assay coefficients of variations (CVs) were less than 
0.8% and 1.7%, respectively, for all examinations. 
The sensitivity of the TG assay was 4 mg/ml, while 
intra- and inter-assay CVs were 1.5% and 1.8%, 
respectively. 
Apolipoprotein A (ApoA) and ApoB100 con-
centrations were measured using an in vitro human 
N-Antiserum anti-ApoA and ApoB100 kit (Dade 
Behring, Marburg, Germany). The sensitivity of the 
ApoA assay was 1.01 mg/ml. Intra- and inter-assay 
CVs were 2.2% and 5.7%, respectively. The sensi-
tivity of the ApoB100 assay was 1.22 mg/ml, while 
intra- and inter-assay CVs were 1.9% and 2.4%, 
respectively. 
A N Reagent Latex lipoprotein(a) [Lp(a)] kit 
was used for lipoprotein a [Lp(a)] (Dade Behring, 
Marburg, Germany). The sensitivity of the assay was 
0.2 mg/dl. Intra- and inter-assay CVs were 2.1% and 
2.8%, respectively. 
Genomic DNA was extracted from peripheral 
blood by a standard procedure18. 
Type of LDLR Mutation
The LDL-R mutations were divided in 2 groups 
according to their residual function as previously 
reported in literature18: (1) the receptor-negative 
mutations or null alleles (R-N) contained all class 1 
mutations, some missense class 2A mutations, large 
rearrangements (except the 2.5-kb deletion, which 
is a class 3 and 5 mutation), mutations resulting in a 
deletion of the translation initiation signal, and early 
stop codons; (2) the receptor-defective mutations 
(R-D) contained class 2B to 6 mutations19. The mis-
sense mutations were included in receptor-defective 
group if the residual receptor activity was > 55% in 
heFH19. 
Assessment of Endothelial-Dependent Flow-mediated 
Vasodilation of the Brachial Artery
A single experienced sonographer performed all 
the measurements after a fasting night, in a noiseless 
and properly temperate area. Subjects had not physi-
cal exercise and were instructed not to take caffeine 
for 24 h before testing. An ultrasound system ACU-
SON 7.0 mHz equipped with vascular software for 
two-dimensional (2D) imaging, color Doppler and 
high-frequency vascular transducer was used. The 
test performance followed standardized protocols for 
adult, due to the lack of specific guidelines for the child 
in literature20.
The brachial artery was visualized longitudinally 
above the antecubital fossa. The diameter of the ves-
sel was constantly monitored through an M mode. To 
generate a flow stimulus in the brachial artery, a sphyg-
momanometric cuff was positioned above the forearm 
and, after the acquisition of the rest image, inflated to 
a suprasystolic pressure to obstruct the artery for about 
5 minutes. A following short reactive hyperemia pro-
voked by the cuff deflation resulted in a dilation of the 
vessel. The longitudinal image of the artery was taped 
continuously from 30 seconds before to 3 minutes 
after cuff deflation. To measure the hyperemic flow, a 
mid-artery pulsed Doppler signal was acquired upon 
immediate cuff release and no later than 15 seconds 
after cuff deflation21. FMD was typically expressed as 
the change in post-stimulus diameter as a percentage 
of the baseline diameter21. 
Statistical Analysis
All normally distributed variables (height, BMI) 
were expressed as mean ± SDS. Data not normally 
distributed (age, TC, LDL-C, TG, HDL-C, ApoA, 
ApoB100, Lp(a), FMD) were log-transformed to 
approximate normality and expressed as mean ± SDS. 
The comparisons among auxological, biochemical and 
FMD data between heFH children and controls and 
in heFH subgroups (male vs. female; change in puber-
tal stage; R-D vs. R-N; positive family history pCVD 
vs. negative) were performed using U Mann-Whitney 
test. Wilcoxon matched-pairs test assessed the lon-
gitudinal differences in auxological, biochemical and 
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FMD data in each subgroup. Univariate analysis was 
performed to correlate variables and Pearson’s r coef-
ficient was calculated. In multiple regression analysis, 
we identified Δ FMD (variation of FMD values along 
time) as the dependent variable; independent variables 
were gender, presence of pCVD, changes in pubertal 
development, type of mutation (as a dichotomus vari-
able) and the demographic and biochemical character-
istics (duration of follow-up, variation in BMI-SDS 
and lipid parameters), which showed an association 
with the dependent variable in univariate analysis at 
15% significance level. 
Statistical significance was inferred at a p value 
of < 0.05.
Results
Table 1 enlisted baseline clinical and instrumental 
features of heFH patients and controls. Mean FMD 
values did not vary between groups. 
Along follow-up, despite an improvement in TC 
(309 .29 ± 33.71 vs. 270.95 ± 48.96 mg/dl, p 0.001) 
and ApoB100 (153.57 ± 21.13 vs. 119.13 ± 25.18 mg/
dl, p 0.004) levels, FMD got worse in the 54% (13/24) 
of heFH and, at the end of follow-up, the 66% (16/24) 
of heFH patients showed a pathological FMD. 
A total of 16 different mutations were detected 
among heFH patients. We found 10 null alleles in 13 
children and 6 receptor-defective mutations in 11 chil-
dren. At baseline, no anthropometric and biochemical 
parameters differed between groups (R-N vs. R-D) 
(table 2), but FMD mean values was documented 
pathological only in R-N (table 3). On diet, TC (Δ 
TC: -36.53 ± 41.71 and -40.45 ± 49.09 mg/dl in 
R-N and R-D, respectively) and Apo-B100 levels (Δ 
ApoB100: -31.66 ± 23.67 and -9.14 ± 56.56 mg/dl in 
R-N and R-D, respectively) significantly improved in 
both groups (table 4). Surprisingly, FMD mean values 
deteriorated only in R-D (table 3). 
According to gender, at baseline only heFH 
males presented a non-pathological mean FMD 
value (table 3) even if their LDL-C levels were higher 
than in females (M vs. F: 239.91± 37.65 vs. 205.52 ± 
41.98 mg/dl, p 0.040) (table 2). Nevertheless, along 
time, mean FMD values attenuated in both genders 
Table 1. Baseline anthropometric and vascular features of heFH patients and healthy controls.
heFH (N= 24) Controls (N= 24) p-value
% males 50% 50% /
% puberty 8/24 (34%) 10/24 (41%) /
Age (years) (median; range) 9.71 (4.2 – 19.53) 10.29 (2 - 16.00) 0.39
BMI SDS (mean ± SDS) 0.24 ± 1.21 0.43 ± 0.94 0.45
FMD (%) (mean ± SDS) 7.67 ± 9.26 11.18 ± 7.28 0.09
Table 2. Baseline BMI SDS and lipid profile according to heFH-subgroups. 
Gender LDL-R mutation CVD Family history
M F R-D R-N pCVD+ pCVD-
BMI SDS 0.47 ± 1.24 -0.01 ± 1.18 -0.04 ± 1.26 0.47 ± 1.16 -0.08 ± 1.12 0.69 ± 1.24
TC (mg/dl) 313.58 ± 39.23 305.00 ± 28.23 319.18 ± 32.31 300.92 ± 33.80 299.92 ± 32.12 322.40 ± 32.97
LDL-C (mg/dl) 239.91± 37.65 205.52 ± 41.98* 239.78 ± 35.55 208.27 ± 44.28 210.40 ± 47.43 239.96 ± 29.32
HDL-C (mg/dl) 51.25 ± 13.78 53.66 ± 10.37 47.72 ± 9.48 56.46 ±12.76 52.64 ± 11.32 52.20 ± 13.50
TG (mg/dl) 90.83 ± 38.88 78.41 ± 19.42 86.27 ± 42.23 83.23 ± 17.84 75.28 ± 20.31 97.70 ± 38.60
ApoA (mg/dl) 123.58 ± 22.02 136.11 ± 16.98 121.80 ± 18.32 135.45 ± 21.09 126.41 24.07± 132.33 ± 15.38
ApoB100 (mg/dl) 151.33 ± 25.74 156.55 ± 13.69 159.50 ± 19.52 148.18 ± 21.97 148.58 ± 19.51 160.22 ± 22.48
Lp(a) (mg/dl) 47.54 ± 29.96 39.80 ± 31.86 50.81 ± 33.88 36.20 ± 25.45 42.72 ± 25.89 45.10 ± 36.04
Data are reported as mean±SD. Legend * p< 0.05 between groups.
Acta Biomed 2021; Vol. 92, N. 5: e2021343 5
(table 3). No other anthropometric and biochemical 
differences were detected at baseline and at the end 
of follow-up between genders (table 2 and 4). Only 
among females, TC (305.00 ± 28.23 vs. 261.33 ± 
32.72 mg/dl, p 0.004) and ApoB100 (156.55 ± 13.69 
vs. 111.37 ± 13.87 mg/dl, p 0.04) levels significantly 
decreased on diet (table 4). 
Analyzing data according to pubertal changes, 
heFH group was divided in: patients already puber-
tal at baseline and patients still in pre-puberty at the 
end of follow-up (U, unchanged; 11 patients; 4 males) 
and patients who experienced puberty during follow-
up (C, changed; 13 patients; 8 males). At the end of 
follow-up, C presented an unfavorable lipid levels, in 
particular lower HDL-C and ApoA and higher TG 
and ApoB100 levels than U (table 4). Nevertheless, 
mean FMD values did not differ between groups (U 
vs. C: 8.70 ± 4.46 vs. 5.10 ± 8.94, p 0.32).
14 heFH patients (58%) have a positive familial 
history of pCVD. They presented a significant reduc-
tion of TC (Δ TC: -35.35 ± 45.20 mg/dl, p 0.01) and 
ApoB100 levels (Δ ApoB100: -24.75 ± 24.60, p 0.035) 
along follow-up, but LDL-C concentrations signifi-
cantly improved only in pCVD- group (Δ LDL-C: 
- 43.36 ± 49.42, p 0.02) (table 4). No differences in 
FMD mean values were detected between groups at 
baseline and at the end of follow-up (table 3).
In heFH group, Δ FMD correlated negatively 
only with Δ LDL-C (r -0.21, p < 0.05). 
Multiple regression analysis (model SE 8.81, R2 
0.49, p 0.025) identified gender (level of effect: male; 
β -0.46, p 0.03), puberty (level of effect: progression in 
Table 4. BMI SDS and lipid profile according to heFH-subgroups at the end of follow-up. 
Gender LDL-R mutation CVD Family history Pubertal change
M F R-D R-N pCVD+ pCVD- U C
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Data are reported as mean±SD. Legend: * p< 0.05 between groups; ° p < 0.05 vs. baseline
Table 3. Baseline and longitudinal FMD according to heFH-subgroup. 
Gender LDL-R mutation CVD Family history
M F R-D R-N pCVD+ pCVD-
FMD at baseline (%) 11.55 ± 7.89 3.80 ± 9.18* 10.00 ± 9.32 5.70 ± 9.10 7.30 ± 9.11 8.19 ± 9.95
FMD at follow-up (%) 6.73 ± 7.49 6.77 ± 7.50 2.95 ± 8.02 9.96 ± 4.99 * 7.95 ± 7.09 5.07 ± 7.70
ΔFMD - 4.81 ± 10.90 2.97 ± 12.99 -7.05 ± 12.69 4.26 ± 9.80 0.65 ± 12.36 -3.12 ± 12.73
Data are reported as mean±SD. Legend * p< 0.05 between groups.
Acta Biomed 2021; Vol. 92, N. 5: e20213436
puberty; β -0.61, p 0.03) and Δ BMI SDS (β -0.39, p 
0.03) as main independent predictor factors of ΔFMD. 
Discussion
Even if atherosclerosis is clinically evident only in 
adulthood, atherogenesis starts early in childhood 22. 
Hypercholesterolemia is a significant risk factor for the 
early structural changes of atherosclerosis and for late 
CVD and mortality. Fatty streak, considered the first 
sign of evident atherosclerosis, can be seen in fetuses if 
exposed to maternal hypercholesterolemia5, 23. Later in 
life, not only genetic background but also environmen-
tal modifiable risk factor such as obesity and diet could 
increase the atherosclerotic risk. 
Endothelial dysfunction is an essential early event 
in atherogenesis24, 25. In animal models and in humans, 
both spatial and temporal correlations between 
endothelial dysfunction and coronary atherosclero-
sis have been already demonstrated25, 26. Moreover, 
experiments have already documented the induction 
of endothelial injuries by hypercholesterolemia, par-
ticularly by the LDL component27, 28. 
To measure the degree of atherosclerosis, several 
surrogate markers, appearing long before clinical symp-
toms arise, as FMD, have been evolved. Our results 
show that endothelial function, investigated through 
FMD, is not worse in children as young as pre-scholar 
and scholar age with an altered lipid profile in compari-
son to healthy normo-lipidemic controls. Nevertheless, 
it seems to deteriorate rapidly along follow-up in more 
than half of heFH children and adolescents, despite 
an improvement of lipid profile. Data in literature are 
conflicting. Among studies that investigated FMD in 
children and adolescents with FH, several have found 
significantly impaired FMD in the superficial femo-
ral 11,24 or in the brachial artery29-33. On the contrary, 
two studies have reported no differences in FMD 
between children with FH and healthy controls34, 35. 
Comparing our data with previous ones11, 24, 29-33, we 
suppose that children in our study might be too young 
to achieve differences in the markers of atherosclerosis. 
Moreover, our study supports the hypothesis that in 
early ages not only the presence of a major risk fac-
tor (e.g. hypercholesterolemia) but maybe a cluster of 
pro-atherogenic conditions and their persistence along 
time, could influence the endothelial function. In fact, 
on one side, we demonstrate a significant correlation 
between LDL-C variation and FMD progression in 
youths with heFH, as expressed in the correlation 
analysis. Similar results were already reported in adult 
heFH patients 33, 36. On the other side, data confirm 
that the lipid profile and the development of CVD 
can be variable among FH individuals, even when car-
rying similar functional mutations. Subgrouping our 
children and adolescents according to type of muta-
tion, FMD mean values was documented pathological 
only in R-N at baseline. This was an expected result: 
Bertolini et al., investigating 264 children with heFH, 
already demonstrated in 2009 that patients carrying 
a LDL-R-N mutation had a more severe phenotype, 
in terms of plasma lipid levels and intima-media-
thickness and a higher prevalence of premature CVD 
in first-degree relatives37. Nevertheless, in our study, 
along follow-up, FMD mean values deteriorated only 
in R-D, despite a significant improvement in TC and 
Apo-B100 levels and, thus, regardless the functional 
type of mutations. Interestingly, as presented by Vla-
hos et al., also in our study, lipid parameters cannot 
explain solely the complete variability of FMD within 
the subgroups of heFH children33. Other data com-
ing from adult patients do not clarify yet the effect of 
different LDL-R mutations on CVD 38. These data 
have not to be interpreted as conflicting: the better a 
patient controls LDL-C levels across time, the better 
she/he could preserve her/his vascular function. Nev-
ertheless, it is imperative to better understand how 
elevated LDL-C levels can induce a proinflammatory, 
proatherogenic state or which other mechanisms (e.g. 
inflammatory, immune and haemostatic mechanisms) 
and/or mediators are involved. FH subjects with 
maternal inheritance have higher all-cause mortality 
than FH subjects with paternal inheritance due to an 
exposition to an unfavorable “in utero” environment 39. 
Considering our results, we could speculate that the 
majority of our R-D patients may have a maternal FH 
inheritance (data not shown). 
To our knowledge, only few studies evaluated lon-
gitudinally FMD in the same population of FH chil-
dren and adolescents30. In these previous papers, the 
study period lasted usually no more than few months30, 
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while the median length in our study was 4.52 years. 
This is one of the major strength of the present study 
together with the homogeneity of the population. All 
our patients underwent dietary therapy (TLCs diet); 
the key-treatment of every dyslipidemia, and no one 
was on statin therapy. If few studies in heFH pediatric 
populations demonstrated improvement in vascular 
function with statin therapy30, 40, in our study dietary 
treatment in heFH childhood does not seem to pre-
vent the gradual deterioration of endothelial function, 
as similarly supposed in previous publications41. 
In our study, living in a family with heritage of 
pCVD does not influence longitudinal changes of 
FMD in childhood. Our data are far from what has 
been already demonstrated in literature: in 2002, de 
Jongh et al. documented a more impaired FMD in FH 
patients (14.6 ± 2.2 years) with positive family history 
of pCVD than those without31; Guardamagna et al. in 
2009 concluded that children with heFH and family 
history of pCVD had higher LDL-C and ApoB100 
levels and greater aortic and carotid intima media 
thickness than those with negative family history37. 
Considering the early age of our population, no 
differences between genders were expected. In the pre-
sent study, after follow up, mean FMD values did not 
vary between males and females, even if the trend of 
its development was opposite across time: in males, 
FMD level deteriorated progressively, while females 
showed an amelioration from baseline concomitant to 
an improvement of TC and ApoB100 levels. Moreo-
ver, being male was identified as one of the independ-
ent predictive factors of FMD attenuation across time, 
together with the experience of pubertal changes and 
the worsening of BMI SDS, as multiple regression 
analysis showed. Taking into account the changes of 
lipid assessment during puberty, we have to consider 
that, among the study population, 8 males (67%) and 
only 5 females (42%) experienced puberty during fol-
low-up. In the general population, throughout puberty, 
levels of TC, LDL-C and non-HDL-C decreased, TG 
in males increased, and HDL-C and TG in females 
showed no changes42. In particular, LDL-C levels rose 
during stage 3 of development in males43. Nevertheless, 
in our study, subjects getting into puberty presented an 
unfavorable lipid levels and no changes in FMD evalu-
ation in comparison to patients still in pre-puberty at 
the end of follow-up or already in puberty at baseline. 
Therefore, puberty could hardly justify the trend of 
FMD in males.
As many other chronic conditions, FH requires 
early intervention as well as careful surveillance to 
maximize long-term vascular consequences-free sur-
vival. Recommendations have encouraged prescribing 
statins from the age of 8 years or younger in selected 
patients 44. Our findings further support these recom-
mendations: later the prevention of atherosclerosis is 
begun, less effective it would be, because it has not only 
to target the ongoing risk factors, but also to treat and 
to regress an already existing pathology.
Study limitations
There are some limitations in our study, as men-
tioned above. Firstly, data interpretation should con-
sider the exiguity of our population and its youngness 
(median age 9.71 years) that could seem apparently 
precocious to detect even subclinical CV alteration. 
Moreover, the lack of a standard method to moni-
tor dietary adherence of patients, do not allow us a 
clear deduction of the effect of diet alone on FMD 
progression and, therefore, in later CV rescue. On the 
other side, major strengths include the homogeneity 
of our population together with the length of the 
follow-up (median 4.52 years). In fact, in our study, 
the same population that at baseline was accurately 
and completely characterized in anamnestic, anthro-
pometric and biochemical terms was longitudinally 
evaluated and we could speculate that, over follow up, 
potential confounding environmental factors remain 
constant. 
Conclusions
Although monogenic, FH is characterized by a 
substantial variation in the onset and severity of ath-
erosclerotic disease symptoms. Our data support that 
additional metabolic atherogenic risk factors (being 
male, BMI-SDS) and the effect of environment, in 
association with the genetic defect, are supposed to 
influence the clinical phenotype of FH maybe through 
synergistic interactions or additive effects. 
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In FH, the baseline atherosclerotic risk, its pro-
gression and the response to treatments could be 
serially assessed through a noninvasive subclinical 
instrument as FMD. Actually, we could only specu-
late that, if a clear correlation between FMD changes 
and cardiovascular outcomes will be defined indepen-
dently of LDL-C levels, the clinical practice could be 
enriched by the routinely use of such surrogates.
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